ViroPharma, Inc. (NASDAQ:VPHM)

CAPS Rating: 4 out of 5

A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.

Results 161 - 168 of 168 : « Previous 4 5 6 7 8 9

Recs

2
Member Avatar coveman100 (74.63) Submitted: 8/27/2006 8:36:48 PM : Outperform Start Price: $10.98 VPHM Score: +74.64

a raging value play combined w/tremendous growth potential

Recs

8
Member Avatar cthielen (68.95) Submitted: 8/24/2006 3:22:41 PM : Outperform Start Price: $11.00 VPHM Score: +74.86

new products coming on line. Lots of cash to back it up. Over beat down.

Recs

7
Member Avatar Monteplus3 (< 20) Submitted: 8/23/2006 8:46:15 PM : Outperform Start Price: $10.09 VPHM Score: +90.53

Market has over reacted to possible duplication of product by a competitor. Fundamentals are still strong.

Recs

2
Member Avatar jwbasden (50.56) Submitted: 8/23/2006 2:35:56 AM : Outperform Start Price: $10.22 VPHM Score: +88.72

good value

Recs

3
Member Avatar riffology (34.78) Submitted: 8/18/2006 10:44:56 PM : Outperform Start Price: $9.99 VPHM Score: +93.13

ViroPharma stock declined when the Office of Generic Drugs was going to rule that a generic of their drug Vancocin would be allowed onto the market with clinical testing. Since this is their only commercial product this makes them a risky investment. However, with the current news of the milestone reached with Wyeth and the possibility that the Office of Generic Drugs may require the generic version of Vancocin to be tested before they will wllow it on the market I believe ViroPharma is headed for an uptick in their price.

Recs

1
Member Avatar admiralxavier (< 20) Submitted: 8/17/2006 8:30:48 PM : Outperform Start Price: $9.45 VPHM Score: +104.37

Stock has been hamered over the past 4 months -partly for some good reasons- but I believe that the market way overreacted. I am hoping for a correction early next year

Recs

4
Member Avatar RBBioContest06 (54.27) Submitted: 5/31/2006 10:33:58 PM : Outperform Start Price: $9.85 VPHM Score: +93.23

Picked by ria12

Recs

10
Member Avatar PrincetonAl (90.73) Submitted: 5/25/2006 4:40:19 AM : Outperform Start Price: $9.38 VPHM Score: +103.24

Check out the P/E.

Viropharm is priced as if generic competition is a given. Any significant delays that allow its pipeline to mature, or any stumbles will allow it to rebound significantly from where it is, $13 - $15, allowing for a 40%+ gain from where it is.

While speculative in nature, the short-term significant upside vs. the lack of likely significant triggers in the short-term to the downside mean this is a reasonable play for a smaller, speculative part of a portfolio.

Results 161 - 168 of 168 : « Previous 4 5 6 7 8 9

Featured Broker Partners


Advertisement